eprintid: 10157002
rev_number: 10
eprint_status: archive
userid: 699
dir: disk0/10/15/70/02
datestamp: 2022-10-10 07:33:34
lastmod: 2023-08-16 14:56:37
status_changed: 2022-10-10 07:33:34
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Gardner, Annelys Roque
creators_name: Ma, Yifei
creators_name: Bacchetti, Peter
creators_name: Price, Jennifer C
creators_name: Kuniholm, Mark H
creators_name: French, Audrey L
creators_name: Gange, Stephen
creators_name: Adimora, Adaora A
creators_name: Minkoff, Howard
creators_name: Kassaye, Seble
creators_name: Ofotokun, Igho
creators_name: Rosenberg, William
creators_name: Kovacs, Andrea AZ
creators_name: Tien, Phyllis C
title: Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment
ispublished: pub
divisions: C10
divisions: G91
divisions: B02
divisions: UCL
divisions: D17
keywords: APRI, ELF, FIB-4, HIV, direct-acting antiviral therapy, enhanced liver fibrosis score, hepatitis C
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: BACKGROUND: The trajectory of liver fibrosis is not well understood in the contemporary era of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) therapy. METHODS: We assessed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) in 116 women with HIV/HCV coinfection over a 4-year period. Random-effects linear regression models examined the rate of fibrosis change 1-2 years before starting HCV treatment, within 1 year before starting (peri-HCV treatment), within 1 year after and 1-2 years post-HCV treatment in unadjusted and adjusted models including age, race, and changes from pretreatment of factors that might affect fibrosis (eg, alcohol, integrase strand inhibitor [INSTI] use, waist circumference, CD4 count). RESULTS: INSTI use nearly doubled from pre- to peri-HCV treatment. In unadjusted analysis, there was a 3.3% rate of rise in ELF pre-HCV treatment, 2.2% and 3.6% rate of decline during the peri- and 1-year post-HCV treatment period, respectively, followed by a 0.3% rise. Similar findings were observed for APRI and FIB-4. There was little effect on the estimated fibrosis trajectories after adjustment. CONCLUSIONS: The apparent lack of decline in biomarkers of liver fibrosis beyond 1 year after HCV cure suggests that continued monitoring of liver fibrosis and interventions to mitigate progression in people with HIV after HCV cure remains essential.
date: 2023-06
date_type: published
publisher: Oxford University Press (OUP)
official_url: https://doi.org/10.1093/infdis/jiac315
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1970009
doi: 10.1093/infdis/jiac315
medium: Print-Electronic
pii: 6650396
lyricists_name: Rosenberg, William
lyricists_id: WMCRO67
actors_name: Rosenberg, William
actors_id: WMCRO67
actors_role: owner
funding_acknowledgements: U01-HL146241 [NIH HHS]
full_text_status: public
publication: Journal of Infectious Diseases
volume: 227
number: 11
pagerange: 1274-1281
pages: 8
event_location: United States
issn: 0022-1899
citation:        Gardner, Annelys Roque;    Ma, Yifei;    Bacchetti, Peter;    Price, Jennifer C;    Kuniholm, Mark H;    French, Audrey L;    Gange, Stephen;                             ... Tien, Phyllis C; + view all <#>        Gardner, Annelys Roque;  Ma, Yifei;  Bacchetti, Peter;  Price, Jennifer C;  Kuniholm, Mark H;  French, Audrey L;  Gange, Stephen;  Adimora, Adaora A;  Minkoff, Howard;  Kassaye, Seble;  Ofotokun, Igho;  Rosenberg, William;  Kovacs, Andrea AZ;  Tien, Phyllis C;   - view fewer <#>    (2023)    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.                   Journal of Infectious Diseases , 227  (11)   pp. 1274-1281.    10.1093/infdis/jiac315 <https://doi.org/10.1093/infdis%2Fjiac315>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10157002/1/ELF_trajectory_in_HIV-HCV_manuscript_revised%205-9-2022%20FINAL.pdf